• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Thermo Fisher’s Datavant Deal and Clario Financing Altering The Investment Case For TMO?

    Simply Wall St·02/19/2026 15:30:12
    Listen to the news
    • Earlier in February 2026, Thermo Fisher Scientific’s PPD clinical research business announced a data collaboration with Datavant and completed a US$3.80 billions multi‑tranche senior notes offering, largely to help fund its pending acquisition of Clario Holdings.
    • This combination of enhanced real‑world data capabilities and fresh long-term financing underscores how Thermo Fisher is reinforcing its position across clinical research and evidence generation.
    • Next, we’ll examine how integrating Datavant’s real-world data platform could influence Thermo Fisher’s investment narrative and long-term growth drivers.

    Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

    Thermo Fisher Scientific Investment Narrative Recap

    To own Thermo Fisher Scientific, you need to believe in its role as an end to end partner for pharma and biotech, with data, services and instruments tightly integrated into clinical development. The Datavant collaboration and new US$3.80 billion notes issue reinforce that story by deepening real world evidence capabilities and funding the Clario deal, but they also keep balance sheet and execution risk in focus as Thermo Fisher leans further into services and data rich workflows.

    The Datavant agreement looks especially relevant here because it directly supports one of Thermo Fisher’s key growth drivers: using AI and advanced analytics to speed up clinical trials and evidence generation. This builds on prior digital partnerships, such as the OpenAI collaboration, and ties into the broader catalyst of becoming a more embedded, recurring partner across clinical research, outsourcing and lab services, rather than relying solely on one off instrument sales.

    Yet while these moves expand Thermo Fisher’s opportunity set, investors should also be aware that rising debt for acquisitions and integration risk could...

    Read the full narrative on Thermo Fisher Scientific (it's free!)

    Thermo Fisher Scientific's narrative projects $50.0 billion revenue and $9.0 billion earnings by 2028.

    Uncover how Thermo Fisher Scientific's forecasts yield a $641.57 fair value, a 25% upside to its current price.

    Exploring Other Perspectives

    TMO 1-Year Stock Price Chart
    TMO 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming revenue could reach about US$52.7 billion and earnings US$9.5 billion, yet this new data collaboration may either strengthen that upbeat story or highlight how sensitive those expectations are to risks like acquisition execution and growing protectionism.

    Explore 11 other fair value estimates on Thermo Fisher Scientific - why the stock might be worth as much as 45% more than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Curious About Other Options?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.